Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam Pharmaceuticals
Pharma
Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged
While Eli Lilly and Novo Nordisk experienced market cap declines in Q3, BMS, Gilead and Sanofi saw their value increase, according to GlobalData.
Kevin Dunleavy
Nov 8, 2024 5:00am
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Apr 22, 2024 10:55am
Alnylam embarks on campaign to drive hATTR amyloidosis diagnoses
Mar 13, 2024 10:30am
Alnylam files yet another patent suit against Pfizer and Moderna
May 30, 2023 10:55am
Alnylam runs new rare disease awareness series on social media
Feb 22, 2023 9:20am
NICE signs off on rare disease therapies from Alnylam, PTC
Jan 19, 2023 1:21pm
